Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous Tumors

Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous Tumors

Sorafenib is a multi-kinase small molecule inhibitor that targets serine/threonine and tyrosine kinases including the RAF kinase family, VEGFR-2, and PDGFR. The aim of this study was to evaluate the systemic pharmacokinetics of a previously defined tolerable oral dose of sorafenib in tumor-bearing d...

Full description

Bibliographic Details
Main Authors: Jacob R. Cawley, Samuel D. Stewart, Jonathan Paul Mochel, Sridhar Veluvolu, Chand Khanna, Joelle M. Fenger
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Veterinary Science
Subjects:
sorafenib
multi-target kinase inhibitors
pharmacokinetics
dog
cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fvets.2022.888483/full

Internet

https://www.frontiersin.org/articles/10.3389/fvets.2022.888483/full

Similar Items